Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diabetic Macular Edema Treated With Ozurdex (DMEO)

Trial Profile

Diabetic Macular Edema Treated With Ozurdex (DMEO)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Pharmacodynamics
  • Acronyms DMEO
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 15 Dec 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top